Background The risk of delayed autoimmunity occurring months or years after
discontinuation of immunotherapy is frequently asserted in the literature. However, specific …

Immunotherapy with immune checkpoint inhibitor (ICI) monoclonal antibodies has shown to
be an effective therapeutic alternative in several malignant tumors. However, adverse effects …

Objective Little has been published describing hypophysitis after nivolumab or
pembrolizumab treatment. We aimed to (i) assess the risk of hypophysitis following …

Objective Immune checkpoint inhibitors have introduced a new and heterogeneous class of
immune-related adverse effects, with the endocrine system being a predominant target for …

Background Adrenal insufficiency (AI) represents a rare, yet potentially life-threatening
immune checkpoint inhibitor (ICI)-related adverse event. The clinical characteristics of ICI …

Abstract Purpose Immune checkpoint inhibitors (ICIs) are of great success in cancer therapy.
This study aimed to identify adrenal insufficiency (AI) associated with immune checkpoint …

Immune checkpoint inhibitors (CPIs) have recently become a cornerstone for the treatment
of different advanced cancers. These drugs have the ability to reactivate the immune system …

Background Several immune checkpoint inhibitors have been implemented for cancer
treatment which have shown some degree of antitumor effcacy, while immune-related …

Immunotherapy has transformed the treatment of cancer by restoring the power of the
immune system against tumor cells. Disruption of the innate immune inhibition has …

Objective Programmed cell death‐1 (PD‐1) blockade therapy, an immune checkpoint
treatment, can induce hypophysitis or hypopituitarism as an immune‐related adverse event …